NCT03957304 is a Phase 2 clinical trial of Dexmedetomidine in Laceration Repair, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

What drugs are being tested in NCT03957304?

Interventions in NCT03957304: Dexmedetomidine.

What condition does NCT03957304 study?

NCT03957304 studies Laceration Repair.

Is NCT03957304 still recruiting?

NCT03957304 is currently completed. Last updated 7 April 2022.

Last reviewed 2022-04-07 · How we verify

NCT03957304

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intranasal Dexmedetomidine Dose-finding Study

Completed Phase 2 Last updated 7 April 2022

What this trial tests

Phase 2 trial testing Dexmedetomidine in Laceration Repair in 55 participants. Completed in 30 March 2022.

Timeline

20 February 2020

Primary endpoint
30 March 2022

30 March 2022

Quick facts

Lead sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	55
Start date	20 February 2020
Primary completion	30 March 2022
Estimated completion	30 March 2022
Sites	1 location across Canada

Drugs / interventions tested

Dexmedetomidine (dexmedetomidine) — full drug profile →

Conditions studied

Laceration Repair — all drugs for Laceration Repair →

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Who can join

Adults 1 to 10, any sex, with Laceration Repair. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The most common injury prompting an emergency department (ED) visit in children is a cut (laceration) that requires repair using stitches or skin glue. Despite anesthetic (freezing), laceration repair is often very distressful because in young children, most occur on the face. There is currently no effective drug to relieve the distress of laceration repair in children. The goal is to find a safe and effective drug to reduce distress in children undergoing laceration repair. Dexmedetomidine is a new drug that safely provides mild sedation and can be given as a painless nasal spray. Intranasal dexmedetomidine (IND) has been shown to reduce distress in children undergoing painful procedures such as dental work and intravenous insertion. However, no large study has explored IND for laceration repair. In order for research to change the way we care for children, a large study that enrolls children across many paediatric EDs needs to be performed. The first step is to conduct a smaller study to identify the safest and most effective dose. The proposed study plans to enroll 55 children age 1-10 years who require laceration repair.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting

Other London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's trials

Trials by the same sponsor.

NCT07588711 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury · NA · not yet recruiting
NCT07585292 — Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy · NA · not yet recruiting
NCT07510906 — Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer · NA · not yet recruiting
NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
NCT06035809 — Sensory Motor Arousal Regulation Treatment (SMART) Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03957304 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Last refreshed: 7 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03957304.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing